Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, placebo-controlled trial to evaluate the safety, PK and efficacy of PRAX-944 as a non-dopaminergic treatment for the motor symptoms of Parkinson's disease

Next Previous
Trial Profile

A Phase 2, placebo-controlled trial to evaluate the safety, PK and efficacy of PRAX-944 as a non-dopaminergic treatment for the motor symptoms of Parkinson's disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulixacaltamide (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Praxis Precision Medicines

Most Recent Events

  • 27 Apr 2023 Trial design presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 07 Feb 2023 According to a Praxis Precision Medicines media release, topline results are expected in the fourth quarter of 2023.
  • 09 Nov 2022 According to a Praxis Precision Medicines media release, following the positive topline results of Part B of the Phase 2a study, the study design was revised, including changing the primary endpoint to efficacy from safety.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top